INT339903

Context Info Confidence 0.01 First Reported 2010 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 0.18 Pain Relevance 0.22

nucleus (ZGLP1) transmembrane transport (SCN5A)

Anatomy Link Frequency blood 1 SCN5A (Homo sapiens) ZGLP1 (Homo sapiens)

Pain Link Frequency Relevance Heat agonist 5 99.60 Bile 1 84.08 Dopamine 1 80.72 Central nervous system 1 10.48 headache 1 5.00

Disease Link Frequency Relevance Heat Diabetes Mellitus 55 98.12 Weight Loss 2 49.96 Hypoglycemia 15 49.60 Renal Insufficiency 2 42.56 Weight Gain 4 29.12 Obesity 8 5.00 Disease 6 5.00 Pressure Volume 2 Under Development 3 5.00 Body Weight 3 5.00 Hypertension 2 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Agents that can be used as monotherapy or in combination to lower blood glucose and HbA1c include biguanides (metformin), insulin, SUs (glyburide, glipizide, glibenclamide), TZDs (rosiglitazone, pioglitazone), GLP-1 receptor agonists (exenatide, liraglutide), ?

HbA1c Binding (combination) of GLP-1 in blood associated with agonist

1) Confidence 0.01 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.18 Pain Relevance 0.22

General Comments

This test has worked.